Only 20 of 29 FDA-approved biosimilars — for cancer and immune disorders like rheumatoid arthritis — are currently available in the United States, Sean McGowan, head of biosimilars at AmerisourceBergen, a leading drug wholesaler, told the AP. U.S. sales of biosimilars are lower than in Europe due to factors such as red tape, lengthy patents and opposition from brand-name drug makers, the AP said. “These products are highly similar, but much more affordable,” McGowan told the AP.
Semglee is from Viatris Inc., which is seeking FDA approval of another biosimilar of a long-lasting insulin. A typical month’s supply of Semglee injector pens cost about $150 to $190 without insurance, compared to $340 to $520 for Lantus.
From 2020 to 2024, savings from the use of biosimilars will exceed $100 billion in the United States, health data firm IQVIA suggests. The FDA said Wednesday that the biosimilar Semglee is interchangeable with the widely used fast-acting insulin Lantus. A biosimilar is a near copy of an injected biologic medicine that’s manufactured inside living cells, the Associated Press reported.
SOURCE: Associated Press
Visit the National Institute of Diabetes and Digestive and Kidney Diseases for more on insulin. More information
The News Highlights
- FDA Approves Automatic Use of Cheaper Generic Insulin – Consumer Health News
- Check the latest Health news updates and information about health.
For Latest News Follow us on Google News
- Show all
- Trending News
- Popular By week